Clinical outcomes according to treatment arms. (A) Overall survival. A trend toward superior survival of patients randomized to thalidomide emerged 5 years after enrollment on study (P = .09). (B) Event-free survival. Patients randomized to thalidomide have superior event-free survival compared with those treated on the control arm (P = .001). (C) Cumulative CR rates. The frequency of CR is significantly higher on the thalidomide versus control arm (P < .001). (D) Duration of CR from its onset. Durations of complete remission are similar in the 2 study arms. (E) Postrelapse survival. Postrelapse survival tended to be shorter among patients who were initially treated on the thalidomide arm.